Shanghai ShineyoMedical announced the completion of two rounds of financing: a multi-million yuan A++ round invested by EF Burnt Venture and a multi-million yuan A+++ round invested by Baiyun Financial Holdings.

Noliving Biotech Completes CNY Hundreds of Millions in Series C Financing, Further Accelerating Overseas Expansion and Diversified Product Layout.

The world's first visualizable uniform-diameter bionic core-shell microsphere, the latest achievement from Core Medical's bionic core-shell embolic microsphere family — FlashSphere® TraSphere® Polyvinyl Alcohol Embolic Microspheres — has successfully received approval from the National Medical Products Administration (NMPA) for market launch in China, adding a new powerful tool for precise embolization treatment of malignant tumors.

On April 24, the "Human Autologous Polyclonal Regulatory T-cell Injection" independently developed by Shanghai Sairxin Bio received clinical trial approval from the NMPA, marking the entry into the clinical stage of the world's first innovative therapy using intrathecal injection of regulatory T cells (Treg) to treat "ALS."

Recently, the MaxMix™ platform independently developed by Kaituo Biotech successfully achieved GMP scale-up production verification of nearly 20g-grade mRNA-LNP bulk solution. This breakthrough marks a new level in the company’s RNA-LNP production technology capabilities, providing strong support for the industrialization of mRNA vaccines and gene and cell therapy drugs.

ShineyoMedical Announces Three Major Milestones:

1. May 4-8, to be unveiled for the first time at the ARVO Annual MeetingFirst Human Clinical Data of ZM-02 Optogenetic Gene Therapy for Advanced Retinitis Pigmentosa (RP) Presented in Oral Report;

2. Awarded the ARVO Foundation Travel Award in recognition of outstanding scientific research achievements;

3.5 On May 13-17, it will be announced at the 28th Annual Meeting of ASGCTBreakthrough Clinical Data of ZM-01 Gene Therapy for X-linked Retinoschisis Presented in Oral Report, and Poster Presentation of Clinical Data for ZM-02 Therapy.

On April 24, 2025, Central Time, ASCO announced the titles of research abstracts selected for its annual meeting online. Four latest clinical studies related to Huahao Zhongtian's core products, Utidelone Injection and Utidelone Oral Capsules, will be presented at ASCO 2025 through oral presentations and poster displays.